ZANAFLEX Drug Patent Profile

When do Zanaflex patents expire, and when can generic versions of Zanaflex launch?

Zanaflex is a drug marketed by Legacy Pharma Usa and is included in two NDAs.

The generic ingredient in ZANAFLEX is tizanidine hydrochloride. There are eleven drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the tizanidine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zanaflex

A generic version of ZANAFLEX was approved as tizanidine hydrochloride by DR REDDYS LABS INC on July 3^rd, 2002.

Summary for ZANAFLEX

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	146
Clinical Trials:	10
Patent Applications:	4,814
Drug Prices:	Drug price information for ZANAFLEX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZANAFLEX
What excipients (inactive ingredients) are in ZANAFLEX?	ZANAFLEX excipients list
DailyMed Link:	ZANAFLEX at DailyMed

See drug prices for ZANAFLEX

Recent Clinical Trials for ZANAFLEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Henry Ford Health System	Phase 4
National Center for Advancing Translational Science (NCATS)	Phase 2
University of California, San Diego	Phase 2

See all ZANAFLEX clinical trials

Pharmacology for ZANAFLEX

Drug Class	Central alpha-2 Adrenergic Agonist
Mechanism of Action	Adrenergic alpha2-Agonists

Paragraph IV (Patent) Challenges for ZANAFLEX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZANAFLEX	Capsules	tizanidine hydrochloride	2 mg, 4 mg and 6 mg	021447	1	2007-08-10

US Patents and Regulatory Information for ZANAFLEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Legacy Pharma Usa	ZANAFLEX	tizanidine hydrochloride	CAPSULE;ORAL	021447-001	Aug 29, 2002	AB	RX	Yes	No
Legacy Pharma Usa	ZANAFLEX	tizanidine hydrochloride	TABLET;ORAL	020397-002	Feb 4, 2000		DISCN	Yes	No
Legacy Pharma Usa	ZANAFLEX	tizanidine hydrochloride	CAPSULE;ORAL	021447-002	Aug 29, 2002	AB	RX	Yes	Yes

Expired US Patents for ZANAFLEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Legacy Pharma Usa	ZANAFLEX	tizanidine hydrochloride	CAPSULE;ORAL	021447-003	Aug 29, 2002	6,455,557
Legacy Pharma Usa	ZANAFLEX	tizanidine hydrochloride	CAPSULE;ORAL	021447-001	Aug 29, 2002	6,455,557
Legacy Pharma Usa	ZANAFLEX	tizanidine hydrochloride	CAPSULE;ORAL	021447-002	Aug 29, 2002	6,455,557

International Patents for ZANAFLEX

See the table below for patents covering ZANAFLEX around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2005023252

ZANAFLEX Market Dynamics and Financial Trajectory

Last updated: February 21, 2026

ZANAFLEX (tizanidine hydrochloride) is a centrally acting alpha-2 adrenergic agonist used primarily for muscle spasticity and associated pain relief. Its market presence, competitive landscape, and financial prospects have evolved based on regulatory status, patent landscape, and commercialization strategies.

Regulatory Status and Market Environment

ZANAFLEX was originally approved by the FDA in 1996 for managing spasticity. Its patent life expired in the early 2010s, leading to increased generic competition. The drug is marketed under the name ZANAFLEX in the United States and available as a generic in numerous countries.

In recent years, the U.S. patent landscape faced challenges, with patent litigation and patent challenges resulting in generic entry by multiple manufacturers by 2012. The FDA approved several generics post-patent expiry, causing a sharp decline in branded sales.

Market Size and Sales Trends

U.S. Market (Pre- and Post-Patent Expiry)

Year	Branded ZANAFLEX (USD millions)	Generic ZANAFLEX (USD millions)	Total Market (USD millions)
2010	180	0	180
2012	50	130	180
2015	20	80	100
2020	10	60	70

Branded sales declined over 80% from 2010 to 2020, with generics capturing the majority share post-2012. Pricing pressure and decreased market exclusivity led to a drop in revenue.

Global Market

Limited data indicates ZANAFLEX's global sales are modest, with primary markets in North America and select European countries. The drug's off-label uses and combination with other therapies have restricted market expansion.

Competitive and Pricing Dynamics

In the post-patent period, market dynamics shifted significantly. The availability of multiple generics led to a price erosion averaging 50-70%. The average wholesale price (AWP) for ZANAFLEX decreased from approximately USD 7.50 per pill in 2010 to USD 2.00 in 2020, reflecting increased price sensitivity.

Key Competitive Factors:

• Generic Volume: A surge in generic prescriptions led to higher distribution volume but lower revenue per unit.
• Regulatory Barriers: Limited barriers for competing generics resulted in rapid market share capture.
• Supply Chain: Manufacturing and distribution consolidation among generic manufacturers exerted further price pressures.

Financial Projection and Future Outlook

The decline in branded sales is irreversible unless a new patent or formulation innovation emerges. Revenue from ZANAFLEX is expected to continue diminishing, with estimates projecting less than USD 5 million in U.S. branded sales by 2025.

Potential avenues for value realization include:

• Developing extended-release formulations or combination therapies.
• Licensing agreements for new indications or formulations.
• Transitioning to off-patent generic sales with minimal marketing investments.

No recent research and development efforts have been publicly announced by the original patent holder or major generic manufacturers for reformulations.

Industry and Market Considerations

• Patent Landscape: Most patents expired by 2012, limiting exclusivity.
• Regulatory Risks: Future regulations on off-label promotion and abuse potential could influence sales.
• Pricing Environment: Growing emphasis on cost-containment pressures providers limits potential for price increases.

Key Takeaways

• ZANAFLEX initially generated significant revenue, peaking in the early 2000s.
• Patent expiration in 2012 resulted in rapid decline in brand sales due to generic competition.
• The current revenue trajectory is aligned with typical post-patent expiration waning, with minimal prospects for recovery or growth.
• Market strategies should focus on lifecycle management, undisclosed formulations, or alternative indications for potential revenue salvaging.

FAQs

1. What caused the decline in ZANAFLEX sales?
Patent expiration and subsequent entry of multiple generics led to a sharp decline in sales, driven by price competition and market share erosion.

2. Are there any new formulations under development?
No publicly available data indicates ongoing R&D for new formulations or indications for ZANAFLEX.

3. What is the current market share of ZANAFLEX in its primary markets?
It holds a negligible share, with generic competitors dominating the market.

4. Could patent strategies or legal actions reverse the sales trend?
Unlikely, as patent expiries were comprehensive, and legal challenges have been exhausted with no new protected formulations.

5. How does ZANAFLEX compare to other muscle relaxants?
ZANAFLEX’s market share was historically higher, but now it faces stiff competition from other generics and newer agents like baclofen or tizanidine formulations with improved safety profiles.

---

References

[1] U.S. Food and Drug Administration. (2022). ZANAFLEX (tizanidine hydrochloride) prescribing information.

[2] IQVIA. (2022). National Drug Summary: Brand and generic sales data for ZANAFLEX.

[3] U.S. Patent and Trademark Office. (2012). Patent status and expiration dates for ZANAFLEX.

[4] MarketResearch.com. (2021). Muscle spasticity drugs market analysis and forecasts.